報價延遲最少15分鐘:2025/04/29 23:57 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.91 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.39/-0.30
|
|
企業價值
326.77M
|
| 資產負債 |
|
每股賬面淨值
1.95
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
38.63M
|
|
每股收益
0.38
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/04/29 23:57 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies. |